Collectively, these studies suggest that a high pre-treatment, on-treatment, or post-treatment serum ALB–BIL grade is a significant independent prognostic biomarker for poor outcomes in HCC patients after treatment with various therapies. The gene discussed is ALB; the disease is hepatocellular carcinoma.